Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT04872478
Trial Phases:	Phase I	Protocol IDs:	2843-1003 (primary) NCI-2021-13604
Eligibility:	12 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Meryx, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04872478

Summary

This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and
adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or
mixed phenotype acute leukemia. Patients will receive continuous oral MRX-2843 in 28 day
cycles at predefined dose cohorts.

Objectives

This is a Phase I, open-label, non-randomized, dose escalation study in up to 50 adolescent
or adult patients with relapsed/refractory acute myeloid leukemia, acute lymphoblastic
leukemia, or mixed phenotype acute leukemia. Patients will receive a single dose of MRX-2843
followed by continuous oral MRX-2843 in 28 day cycles at predefined dose cohorts.

A dose expansion arm of approximately 12 patients (with 6 patients being FLT3 ITD+ and 6
patients being Mer+/FLT3 WT) will be accrued to further evaluate patients at the RP2D.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.